Link to Full Article Cambridge, UK., 3rd May 2019: Arecor Limited (“Arecor” or “the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology, ArestatTM to develop superior treatments for a range of disease areas, including diabetes, today announces that it has signed a collaboration with a new major global pharmaceutical partner. Under […]
Hot on the heels of our first clinical trials approval, Arecor is delighted to be listed in Business Weekly’s ‘Killer50’, as a leading lifescience innovator. Please see the listing and feature here on Page 12: Link
Cambridge, UK., 20 March 2019: Arecor Ltd (“the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces that a Phase I Clinical Trial Application (“CTA”) for product candidate AT247 has been approved by the Bundesamt für Sicherheit im […]
Cambridge (UK), 11th March 2019, Arecor Limited (‘Arecor’ or the ’Company’), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, is pleased to announce the appointment of Susan Lowther as Chief Financial Officer. Susan was appointed to the board with effect […]
Super-fast product addresses critical unmet need in development of next generation artificial pancreas systems” “Novel formulation significantly accelerates absorption of insulin post injection – accelerating the onset of glucose lowering.” Cambridge, UK., 13 February 2019: Arecor Ltd (“the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for […]
ARECOR LIMITED (“Arecor” or “the Company”) ARECOR TO ATTEND THE 37TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE Cambridge, UK., 5 December 2018: Arecor Ltd (“the Company”), the UK-based specialty pharmaceutical company that develops superior biopharmaceuticals through the application of an innovative formulation technology platform, is pleased to announce today that its executive management team, Dr Sarah […]
Cambridge, UK., 30th October 2018: Arecor Ltd (“the Company”), the UK-based leading formulation technology company, focussed on developing superior biopharmaceuticals via the innovative reformulation of proteins and peptides, continues to build a strong patent portfolio protecting the Company’s proprietary technology and product assets. Arecor is pleased to announce the successful outcome of the opposition proceedings […]
ARECOR LIMITED (“Arecor” or “the Company”) ARECOR JOINS ELITE INVESTOR ROADSHOW TO CHINA “Arecor has joined the London Stock Exchange Group’s latest ELITE mission to China for aspiring companies and will participate in investor roadshow events, in Shenzhen and Hong Kong, between 15th – 18th October 2018” Cambridge, UK., 15 October 2018: Arecor Limited (“the […]
10 September 2018 – Arecor, the UK-based biopharmaceutical formulation company, has raised £6 million from new and existing investors to develop groundbreaking pharmaceutical drugs to transform the treatment of diabetes. The fundraising was led by Calculus Capital, Albion Capital, and Downing Ventures. BioScience Managers Limited, the international healthcare investment firm, advised Downing Ventures. Through the […]